# Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

> **NCT03333369** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Zurich** · enrollment: 65 (actual)

## Conditions studied

- Healthy
- Schizotypal Personality

## Interventions

- **DRUG:** 200 mg levodopa/50 mg benserazide
- **DRUG:** Dextrose

## Key facts

- **NCT ID:** NCT03333369
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-15
- **Primary completion:** 2015-08-13
- **Final completion:** 2015-08-13
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333369, "Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03333369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*